Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes-Reference-Cited by-同舟云学术

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes

Published:2021-06-30 Issue:14 Volume:64 Page:10155-10166
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Trout Robert E.¹^ORCID,Zulli Allison¹,Mesaros Eugen¹,Jackson Randy W.¹,Boyd Steven¹,Liu Bin¹^ORCID,Hamrick Jodie¹,Daigle Denis¹,Chatwin Cassandra L.¹,John Kaitlyn¹,McLaughlin Lisa¹,Cusick Susan M.¹,Weiss William J.²,Pulse Mark E.²,Pevear Daniel C.¹,Moeck Greg¹,Xerri Luigi¹,Burns Christopher J.¹

Affiliation:

1. Venatorx Pharmaceuticals, Inc., 30 Spring Mill Drive, Malvern, Pennsylvania 19355, United States

2. UNT System College of Pharmacy, University of North Texas Health Science Center, 3500 Camp Bowie Boulevard, Fort Worth, Texas 76107-2699, United States

Funder

National Institute of Allergy and Infectious Diseases

National Institutes of Health

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00437

Reference46 articles.

1. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015

2. Carbapenem-resistant Enterobacteriaceae in the community: a scoping review